Figure 3.

Glioma survival by EGFR IHC scores. A: WHO grade II to IV gliomas were segregated according to strength of EGFR IHC. In general, increased EGFR correlated with shorter overall survival. P < 0.0001. However, adjusting for WHO grade in astrocytic tumors eliminated any significant association between EGFR expression and survival in grades II (B), III (C), and IV (D) astrocytomas. See Table 3 for specific intergroup P values. Although the survival curves in EGFR-negative grades II and III astrocytomas appeared favorable, there were not enough cases of each to generate statistical significance (Table 1).